Alcoholic ketoacidosis evaluated with a point-of-care capillary beta-hydroxybutyrate measurement device

被引:1
|
作者
Nishizawa, Takuya [1 ,2 ]
Matsumoto, Takashi [1 ]
Todaka, Takafumi [1 ]
Sasano, Mikio [1 ]
机构
[1] Nakagami Hosp, Dept Intens Care Med, 610 Noborikawa, Okinawa, Okinawa 9042195, Japan
[2] 641-7 Miyazato, Uruma, Okinawa 9042243, Japan
关键词
Alcoholic ketoacidosis; Beta-hydroxybutyrate; Point -of -care capillary beta; hydroxybutyrate measurement device; Emergency department; DIABETIC-KETOACIDOSIS; MULTIPLE COMPLICATIONS; METABOLIC-ACIDOSIS; DIAGNOSIS; DEATH;
D O I
10.1016/j.alcohol.2023.06.005
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: The diagnosis of alcoholic ketoacidosis (AKA) has traditionally been made based only on clinical history and the presence of severe metabolic acidosis with a high anion gap (AG); however, the concentration of beta-hydroxybutyrate (BOHB), a pivotal ketone body in AKA, is not evaluated in most cases. The aim of this study was to clarify the clinical spectrum of AKA in terms of the severity of ketoacidosis by using a point-of-care capillary BOHB measurement device.Methods: This retrospective case series was conducted at a Japanese private teaching hospital. Patients with suspected AKA, based on their clinical history, who underwent BOHB measurement using a point -of-care capillary measurement device in the emergency department, were included. Data on their clinical presentations, blood tests, and treatments were collected, described, and compared between patients with a BOHB concentration higher than 3.0 mmol/L (H-BOHB) and those with a concentration less than 3.0 mmol/L (L-BOHB).Results: A total of 83 patients were included in this study. Sixty-eight patients were categorized as having H-BOHB and 15 as having L-BOHB. Nausea (71%), vomiting (71%), tachycardia (76%), and tachypnea (46%) were commonly observed at presentation. Hyponatremia (46%), hypokalemia (34%), hypomagnesemia (42%), and hyperphosphatemia (41%) were frequent electrolyte abnormalities upon presentation. Rehydration with balanced crystalloids and glucose-containing intravenous fluids, electrolyte supplementation, and thiamine replacement were the major treatments. The mean length of stay in the ICU and hospital were 4.4 and 7.0 days, respectively, with low overall mortality (1%). The H-BOHB and L-BOHB groups did not differ in terms of clinical data. Seventy percent of patients with L-BOHB had severe metabolic acidosis with a high AG due to hyperlactatemia (mean lactate concentration: 8.5 mmol/L).Conclusions: We described the clinical features of AKA measured by using a point-of-care capillary BOHB measurement device. Although certain patients diagnosed with AKA based only on their clinical history had predominant lactic acidosis with minor elevations in BOHB concentration, the BOHB concentration had no effect on the clinical spectrum of AKA in this study.& COPY; 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 50 条
  • [1] Point-of-care beta-hydroxybutyrate testing for assessing diabetic ketoacidosis severity prior to treatment in the emergency department
    Arora, Sanjay
    Probst, Marc A.
    Agy, Chad
    Menchine, Michael
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 94 (03) : E86 - E88
  • [2] Point-of-Care Beta-Hydroxybutyrate Testing for Assessing Diabetic Ketoacidosis Severity Prior to Treatment in the Emergency Department
    Arora, S.
    Probst, M. A.
    Agy, C.
    Menchine, M.
    ANNALS OF EMERGENCY MEDICINE, 2011, 58 (04) : S178 - S178
  • [3] Use of a point-of-care beta-hydroxybutyrate sensor for detection of ketonemia in dogs
    Henderson, Debra W.
    Schlesinger, Daniel P.
    CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE, 2010, 51 (09): : 1000 - 1002
  • [4] Beta-hydroxybutyrate, Glucose and Lactate in the Postmortem Diagnosis of Alcoholic and Hyperglycemic Ketoacidosis
    Bosman, I. J.
    Vincenten, R.
    Pennings, E. J. M.
    CLINICAL TOXICOLOGY, 2011, 49 (03) : 261 - 261
  • [5] Unrecognized persistence of beta-hydroxybutyrate in diabetic ketoacidosis
    Nadgir, UM
    Silver, FL
    MacGillivray, MH
    ENDOCRINE RESEARCH, 2001, 27 (1-2) : 41 - 46
  • [6] Comparison of a Point-of-Care Whole Blood Beta-Hydroxybutyrate System with a Clinical Laboratory Reference Method
    Chin, A. C.
    Koch, D. D.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A104 - A104
  • [7] CLINICAL UTILITY OF BEDSIDE MEASUREMENT OF BETA-HYDROXYBUTYRATE IN THE MANAGEMENT OF DIABETIC-KETOACIDOSIS
    UMPIERREZ, GE
    WATTS, NB
    MIXON, PS
    PHILLIPS, LS
    CLINICAL RESEARCH, 1994, 42 (02): : A117 - A117
  • [8] Comparison of Serum and Point of Care Beta-hydroxybutyrate Measurement in Healthy Children after Overnight Fast
    Parmar, Komalben
    Mosha, Maua
    Williams, Monika
    Weinstein, David
    Riba-Wolman, Rebecca
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 2): : 97 - 98
  • [9] Utilizing Point of Care Testing To Identify Diabetic Ketoacidosis at Emergency Department Triage: Beta-Hydroxybutyrate vs Urine Dip
    Arora, Sanjay
    Peters, Anne L.
    Long, Theodore
    Henderson, Sean O.
    Menchine, Michael
    DIABETES, 2010, 59 : A103 - A103
  • [10] Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis
    Tremblay, Elise Schlissel
    Millington, Kate
    Wu, Yunhong
    Wypij, David
    Yang, Yufan
    Agus, Michael S. D.
    Wolfsdorf, Joseph
    PEDIATRIC DIABETES, 2022, 23 (08) : 1621 - 1627